-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Do Institutions Own Jiangsu gdk Biotechnology Co., Ltd. (SHSE:688670) Shares?
Do Institutions Own Jiangsu gdk Biotechnology Co., Ltd. (SHSE:688670) Shares?
Every investor in Jiangsu gdk Biotechnology Co., Ltd. (SHSE:688670) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
Jiangsu gdk Biotechnology is a smaller company with a market capitalization of CN¥4.1b, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company. Let's take a closer look to see what the different types of shareholders can tell us about Jiangsu gdk Biotechnology.
See our latest analysis for Jiangsu gdk Biotechnology
SHSE:688670 Ownership Breakdown July 13th 2022What Does The Institutional Ownership Tell Us About Jiangsu gdk Biotechnology?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
We can see that Jiangsu gdk Biotechnology does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Jiangsu gdk Biotechnology's earnings history below. Of course, the future is what really matters.
SHSE:688670 Earnings and Revenue Growth July 13th 2022Hedge funds don't have many shares in Jiangsu gdk Biotechnology. Liangbin Zhang is currently the largest shareholder, with 31% of shares outstanding. In comparison, the second and third largest shareholders hold about 31% and 3.8% of the stock. Interestingly, the bottom two of the top three shareholders also hold the title of Senior Key Executive and Member of the Board of Directors, respectively, suggesting that these insiders have a personal stake in the company.
After doing some more digging, we found that the top 2 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. We're not picking up on any analyst coverage of the stock at the moment, so the company is unlikely to be widely held.
Insider Ownership Of Jiangsu gdk Biotechnology
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
It seems that insiders own more than half the Jiangsu gdk Biotechnology Co., Ltd. stock. This gives them a lot of power. So they have a CN¥2.8b stake in this CN¥4.1b business. Most would be pleased to see the board is investing alongside them. You may wish todiscover (for free) if they have been buying or selling.
General Public Ownership
The general public-- including retail investors -- own 21% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
Private Company Ownership
Our data indicates that Private Companies hold 3.0%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for Jiangsu gdk Biotechnology (1 is significant) that you should be aware of.
If you would prefer check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, backed by strong financial data.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
江苏广德科生物科技股份有限公司(上证号:688670)的每一位投资者都应该意识到最强大的股东群体。一般来说,随着公司的成长,机构会增加他们的持股。相反,随着时间的推移,内部人士往往会减少他们的持股。沃伦·巴菲特说,他喜欢“一家由有能力、以所有者为导向的人经营的、具有持久竞争优势的企业”。因此,看到一些内部人持股是件好事,因为这可能表明管理层是以所有者为导向的。
江苏广发生物科技是一家规模较小的公司,市值为41亿元人民币,因此它可能仍在许多机构投资者的雷达下飞行。我们对公司所有权的分析如下所示,机构拥有公司的股份。让我们仔细看看不同类型的股东能告诉我们关于江苏广德科生物科技的什么。
查看我们对江苏广德科生物科技的最新分析
上海证交所:688670所有权明细2022年7月13日关于江苏广发生物科技,机构持股告诉了我们什么?
机构通常在向自己的投资者报告时,以基准来衡量自己,因此一旦一只股票被纳入主要指数,它们往往会对这只股票变得更加热情。我们预计,大多数公司都会有一些机构登记在册,特别是在它们正在增长的情况下。
我们可以看到,江苏广电生物科技确实有机构投资者,他们持有公司很大一部分股票。这表明在专业投资者中有一定的可信度。但我们不能仅仅依靠这一事实,因为机构有时会做出糟糕的投资,就像每个人一样。如果多家机构同时改变对一只股票的看法,你可能会看到股价迅速下跌。因此,下面是江苏广电生物科技的盈利历史,值得一看。当然,未来才是真正重要的。
上海证交所:2022年7月13日收益和收入增长688670对冲基金在江苏广发生物科技的股份并不多。张良斌目前是第一大股东,持有31%的流通股。相比之下,第二大股东和第三大股东分别持有约31%和3.8%的股份。有趣的是,前三名股东中排名垫底的两名股东还分别持有高级关键高管和董事会成员的头衔,这表明这些内部人士拥有公司的个人股权。
在进一步挖掘后,我们发现,前两名股东共同控制着公司一半以上的股份,这意味着他们拥有相当大的权力来影响公司的决策。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。目前,我们没有注意到分析师对该股的报道,因此该公司不太可能被广泛持有。
江苏GDK生物技术公司的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
我通常认为内部人持股是一件好事。然而,在某些情况下,这会让其他股东更难让董事会对决策负责。
看来,内部人士持有江苏广电生物科技股份有限公司一半以上的股份。这给了他们很大的权力。因此,他们在这笔41亿元的业务中拥有28亿元的股份。大多数人会高兴地看到董事会与他们一起投资。您可能希望发现(免费)如果他们一直在买入或卖出。
一般公有制
包括散户投资者在内的普通公众持有该公司21%的股份,因此不能轻易忽视。虽然这群人不一定能发号施令,但它肯定能对公司的运营方式产生真正的影响。
私营公司所有权
我们的数据显示,私营公司持有该公司3.0%的股份。或许有必要对此进行更深入的研究。如果关联方,如内部人士,对这些私营公司中的一家有利害关系,则应在年报中披露。私营公司也可能对该公司拥有战略利益。
接下来的步骤:
虽然考虑拥有一家公司的不同集团是很值得的,但还有其他更重要的因素。例如,我们已经确定江苏广德科生物科技的三个警示(1是重要的),您应该知道。
如果你更愿意看看另一家公司--一家财务状况可能更好的公司--那么不要错过这一点免费令人感兴趣的公司名单,有强劲的财务数据支持。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧